Estimated Healthcare Costs of Melanoma in Australia Over 3 Years Post-Diagnosis
- 208 Downloads
Skin cancer exerts a large and growing burden on health systems. With new pharmacotherapies for metastatic melanoma now available, a contemporary understanding of the cost burden of melanoma control is warranted.
To comprehensively assess the healthcare costs of malignant melanoma diagnosis and treatment in Australia, over 3 years after diagnosis.
We developed a decision-analytic model and micro-costing method to estimate the mean cost per patient for melanoma, incorporating all diagnostic and treatment modalities used in Australia (2017 AU$). By using the de-identified 10% sample of Medicare Benefits Scheme, we analysed health service use and supplemented our analyses with published estimates. We took a health system cost perspective, and addressed input uncertainty with sensitivity analyses.
The mean annual cost per patient for melanoma stage 0/I/II was AU$1681 (US$1175) rising to AU$37,729 (US$26,365) for stage III resectable, and AU$115,109 (US$80,440) for stage III unresectable/IV. Three-year costs for stage III unresectable/IV were AU$187,720. Nationally, the annual estimated cost for treatment of all new cases of in situ and invasive melanomas was AU$201 million (95% CI: AU$187 to AU$216 million). When we included treatments for presumptive melanoma later found to be benign lesions, the estimated annual cost burden reached AU$272 million.
With rapidly rising treatment costs, there is a need to consider a comprehensive melanoma control strategy that includes primary prevention of skin cancers and cost-effective sun protection initiatives.
TE contributed to model development, conceptualisation, data analysis, modelling, writing and editing. CO and DW contributed to model conceptualisation, melanoma knowledge and intellectual inputs. LG contributed to model conceptualisation, data analysis, writing and editing. All authors were involved in writing, editing and approved the final version.
Compliance with Ethical Standards
DW was supported by a Research Fellowship (APP1058522) from the National Health and Medical Research Council of Australia (NHMRC). This work was supported by Program Grants (552429, 1073898) from the NHMRC. TE was supported by the NHMRC Centre for Research Excellence in Sun and Health (APP1001456). No conflicts of interest exist for TE, CO, DW or LG.
- 1.Melanoma Institute Australia. Melanoma facts and statistics. 2016. https://www.melanoma.org.au/understanding-melanoma/melanoma-facts-and-statistics/. Accessed 01 Oct 2016.
- 2.Australian Cancer Incidence and Mortality Books: Melanoma of the skin [database on the Internet]. AIHW. 2015. http://www.aihw.gov.au/acim-books. Accessed: 01 Oct 2016.
- 4.Maio M, Grob JJ, Aamdal S, Bondarenko I, Robert C, Thomas L, et al. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J Clin Oncol. 2015;33(10):1191–6. doi: 10.1200/JCO.2014.56.6018.CrossRefPubMedGoogle Scholar
- 6.The Hon. Sussan Ley MP MfH. New drug listing Keytruda to treat melanoma. 2015. https://www.health.gov.au/internet/ministers/publishing.nsf/Content/health-mediarel-yr2014-ley081.htm. Accessed 01 Oct 2015.
- 7.Pharmaceutical Benefits Scheme [database on the Internet]. 2015. http://www.pbs.gov.au/pbs/home. Accessed: 20 Oct 2016.
- 13.Linkable de-identified 10% sample of Medicare Benefits Schedule (MBS) and Pharmaceutical Benefits Schedule (PBS) [database on the Internet]. 2016. https://data.gov.au/dataset/mbs-sample-10pct-1984-gz. Accessed 07 Nov 2016.
- 15.Veness MJ, Morgan GJ, Palme CE, Gebski V. Surgery and adjuvant radiotherapy in patients with cutaneous head and neck squamous cell carcinoma metastatic to lymph nodes: combined treatment should be considered best practice. Laryngoscope. 2005;115(5):870–5. doi: 10.1097/01.Mlg.0000158349.64337.Ed.CrossRefPubMedGoogle Scholar
- 18.Australian Cancer Network Melanoma Guidelines Revision Working Party. Clinical practice guidelines for the management of melanoma in Australia and New Zealand. Wellington: Sydney and New Zealand Guidelines Group; 2008.Google Scholar
- 20.Niebling MG, Haydu LE, Karim RZ, Thompson JF, Scolyer RA. Pathology review significantly affects diagnosis and treatment of melanoma patients: an analysis of 5011 patients treated at a melanoma treatment center. Ann Surg Oncol. 2014;21(7):2245–51. doi: 10.1245/s10434-014-3682-x.CrossRefPubMedGoogle Scholar
- 22.Tracey E, Kerr T, Dobrovic A, Currow D. Cancer. In: NSW: Incidence and Mortality Report 2008. Sydney: Cancer Institute NSW; 2010.Google Scholar
- 23.Pharmaceutical Benefits Scheme. PBS item reports. 2015. http://medicarestatistics.humanservices.gov.au/statistics/pbs_item.jsp. Accessed 27 Aug 2015.
- 24.Long GV, Flaherty KT, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, et al. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann Oncol Off J Eur Soc Med Oncol. 2017;. doi: 10.1093/annonc/mdx176.Google Scholar
- 29.The Australian Department of Health. MBS online. 2015. http://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/Home. Accessed 27 Aug 2015.
- 30.Australian Institute of Health and Welfare. Admitted patient care 2013–14: Australian hospital statistics. Canberra: Commonwealth Government; 2015.Google Scholar
- 31.Australian Institute of Health and Welfare. Separation statistics by principal diagnosis in ICD-10-AM. Canberra: Commonwealth Government; 2013.Google Scholar
- 33.Australian Institute of Health and Welfare & Australian Association for Cancer Registries. Cancer in Australia: an overview 2012. Canberra: Commonwealth Government; 2012.Google Scholar
- 36.Baade PD, Youl PH, Janda M, Whiteman DC, Del Mar CB, Aitken JF. Factors associated with the number of lesions excised for each skin cancer: a study of primary care physicians in Queensland, Australia. Arch Dermatol. 2008;144(11):1468–76. doi: 10.1001/archderm.144.11.1468.CrossRefPubMedGoogle Scholar
- 39.Australian Institute of Health and Welfare. Health system expenditure on cancer and other neoplasms in Australia, 2008–09. Commonwealth Government. Canberra: AIHW; 2013.Google Scholar
- 40.Australian Institute of Health and Welfare. Health system expenditures on cancer and other neoplasms in Australia, 2000–01. In: Health and Welfare Expenditure series no. 22. Canberra: Commonwealth Government; 2005.Google Scholar
- 43.KPMG. Advanced Melanoma—the real cost of Australia’s national cancer: a report prepared for Melanoma Patients Australia. Sydney; 2014.Google Scholar
- 47.Australian Institute of Health and Welfare. Health expenditure Australia 2010–11. Canberra: Australian Institute of Health and Welfare; 2011.Google Scholar
- 48.The Organisation for Economic Co-operation and Development. What future for health spending? OECD Economics Department Policy Notes. 2013; No. 19.Google Scholar
- 50.Exxedine KMD, Mauger E, et al. Artificial and natural ultraviolet radiation exposure: beliefs and behaviour of 7200 French adults. Euro Acad Dermatol Venereol. 2008;22(2):186–94.Google Scholar